Filing Flows › bioAffinity Technologies (BIAF) › Guidance history
bioAffinity Technologies (BIAF) guidance history: what it guided and what it reported
bioAffinity Technologies gave guidance in 1 earnings release on file since Nov 6, 2026.
Net income
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $12.3M (Nov 6, 2026) | — | to be reported | — |
The latest quarter
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
Questions
Does bioAffinity Technologies beat its guidance?
bioAffinity Technologies gave guidance in 1 earnings release on file since Nov 6, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.